AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Obesity and associated comorbidities are a major health burden, and novel therapeutics to help treat obesity are urgently needed. There is increasing evidence that targeting the amylin receptors (AMYRs), heterodimers of the calcitonin G protein-coupled receptor (CTR) and receptor activity-modifying proteins, improves weight control and has the potential to act additively with other treatments such as glucagon-like peptide-1 receptor agonists. Recent data indicate that AMYR agonists, which can also independently activate the CTR, may have improved efficacy for treating obesity, even though selective activation of CTRs is not efficacious. AM833 (cagrilintide) is a novel lipidated amylin analog that is undergoing clinical trials as a nonselective AMYR and CTR agonist. In the current study, we have investigated the pharmacology of AM833 across 25 endpoints and compared this peptide with AMYR selective and nonselective lipidated analogs (AM1213 and AM1784), and the clinically used peptide agonists pramlintide (AMYR selective) and salmon CT (nonselective). We also profiled human CT and rat amylin as prototypical selective agonists of CTR and AMYRs, respectively. Our results demonstrate that AM833 has a unique pharmacological profile across diverse measures of receptor binding, activation, and regulation. SIGNIFICANCE STATEMENT: AM833 is a novel nonselective agonist of calcitonin family receptors that has demonstrated efficacy for the treatment of obesity in phase 2 clinical trials. This study demonstrates that AM833 has a unique pharmacological profile across diverse measures of receptor binding, activation, and regulation when compared with other selective and nonselective calcitonin receptor and amylin receptor agonists. The present data provide mechanistic insight into the actions of AM833.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 2×
“Overweight and obesity are major risk factors for other diseases including heart disease and stroke, osteoarthritis and some cancers, and among the largest contributors to morbidity and mortality (Blüher, 2019).”
BackgroundRAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134 · cited 1×
“Human RAMP1 and RAMP3 were a gift from Dr. Steve Foord (McLatchie et al., 1998).”
MethodDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Self-citationAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · cited 2×
“However, few drugs have been approved for the treatment of obesity and most have limited efficacy, promoting only around 3-7% weight loss, although higher efficacy is reported for high-dose formulation of the glucagon-like peptide-1 receptor (GLP-1R) agonist, semaglutide (Srivastava and Apovian, 2018; Williams et al.,…”
BackgroundAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“While pramlintide was not optimised for weight reduction, patients treated with this drug exhibited small but significant weight loss providing proof-of-principle that AMYRs could be targeted in humans (Aronne et al., 2007; Aronne et al., 2010).”
BackgroundCloning and characterization of an abundant subtype of the human calcitonin receptor.
Kuestner, R. E., Elrod, R. D., Grant, F. J., Hagen, F. S., Kuijper, J. L., Matthewes, S. L., O'Hara, P. J., Sheppard, P. O., Stroop, S. D., & Thompson, D. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09678-6 · Cited by 149
Morfis, M., Tilakaratne, N., Furness, S. G. B., Christopoulos, G., Werry, T. D., Christopoulos, A., & Sexton, P. M. (2008) · Endocrinology · doi:10.1210/en.2007-1735 · Cited by 134 · cited 14×
“With the more complex fits, the differences between CTR and AMYRs are less pronounced, however, an induction of the expected AMY1R and AMY3R phenotypes could be observed with amylin peptides.”
BackgroundResultSelf-citationSalmon Calcitonin Use and Associated Cancer Risk
Overman, R. A., Borse, M., & Gourlay, M. L. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013509233 · Cited by 96
Research works printed but not linked: 41
- Andreassen, 2014, A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats, Am J Physiol Endocrinol Metab, 307, E24, 10.1152/ajpendo.00121.2014 · DOI · Paper page
- Aronne, 2010, Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial, Obesity (Silver Spring), 18, 1739, 10.1038/oby.2009.478 · DOI · Paper page
- Chelikani, 2007, Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats, Am J Physiol Regul Integr Comp Physiol, 293, R1798, 10.1152/ajpregu.00386.2007 · DOI
- Dal Maso, 2018, Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms, Biochem Pharmacol, 148, 111, 10.1016/j.bcp.2017.12.016 · DOI
- Feigh, 2011, A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats, Diabetes Obes Metab, 13, 911, 10.1111/j.1463-1326.2011.01425.x · DOI · Paper page
- Feinstein, 2011, Retromer terminates the generation of cAMP by internalized PTH receptors, Nat Chem Biol, 7, 278, 10.1038/nchembio.545 · DOI · Paper page
- Ferrandon, 2009, Sustained cyclic AMP production by parathyroid hormone receptor endocytosis, Nat Chem Biol, 5, 734, 10.1038/nchembio.206 · DOI · Paper page
- Furness, 2016, Ligand-dependent modulation of g protein conformation alters drug efficacy, Cell, 167, 739, 10.1016/j.cell.2016.09.021 · DOI · Paper page
- Gingell, 2014, Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors, Endocrinology, 155, 21, 10.1210/en.2013-1658 · DOI · Paper page
- Gingell, 2020, Distinct patterns of internalization of different calcitonin gene-related peptide receptors, ACS Pharmacol Transl Sci, 3, 296, 10.1021/acsptsci.9b00089 · DOI
- Gorn, 1992, Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line, J Clin Invest, 90, 1726, 10.1172/JCI116046 · DOI · Paper page
- Guerreiro, 2013, Preparation and characterization of PEGylated amylin, AAPS PharmSciTech, 14, 1083, 10.1208/s12249-013-9987-4 · DOI
- Gydesen, 2016, KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight, Am J Physiol Endocrinol Metab, 310, E821, 10.1152/ajpendo.00514.2015 · DOI · Paper page
- Gydesen, 2017, Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog, Am J Physiol Endocrinol Metab, 313, E598, 10.1152/ajpendo.00419.2016 · DOI · Paper page
- Gydesen, 2017, A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference, Br J Pharmacol, 174, 591, 10.1111/bph.13723 · DOI · Paper page
- Hay, 2005, Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes, Mol Pharmacol, 67, 1655, 10.1124/mol.104.008615 · DOI · Paper page
- Iepsen, 2015, Liraglutide for Type 2 diabetes and obesity: a 2015 update, Expert Rev Cardiovasc Ther, 13, 753, 10.1586/14779072.2015.1054810 · DOI · Paper page
- Ismail, 2016, Internalized Receptor for Glucose-dependent Insulinotropic Peptide stimulates adenylyl cyclase on early endosomes, Biochem Pharmacol, 120, 33, 10.1016/j.bcp.2016.09.009 · DOI
- Kolterman, 1996, Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM, Diabetologia, 39, 492, 10.1007/BF00400683 · DOI
- Kowalczyk, 2014, Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism, Org Biomol Chem, 12, 8142, 10.1039/C4OB01208A · DOI · Paper page
- Larsen, 2019, The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy, J Pharmacol Exp Ther, 370, 35, 10.1124/jpet.119.257576 · DOI
- Larsen, 2020, The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy, J Pharmacol Exp Ther, 374, 74, 10.1124/jpet.119.263392 · DOI
- Larsen, 2020, Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088: long-lasting improvement in food preference and body weight loss, J Pharmacol Exp Ther, 373, 269, 10.1124/jpet.119.263400 · DOI
- Lutz, 2010, The role of amylin in the control of energy homeostasis, Am J Physiol Regul Integr Comp Physiol, 298, R1475, 10.1152/ajpregu.00703.2009 · DOI · Paper page
- Lutz, 2000, Amylin receptors mediate the anorectic action of salmon calcitonin (sCT), Peptides, 21, 233, 10.1016/S0196-9781(99)00208-9 · DOI
- Mack, 2011, Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide, Diabetes Obes Metab, 13, 1105, 10.1111/j.1463-1326.2011.01465.x · DOI · Paper page
- Mack, 2010, Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight, Int J Obes, 34, 385, 10.1038/ijo.2009.238 · DOI
- Mathiesen, 2021, Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat, Front Endocrinol (Lausanne), 11, 617400, 10.3389/fendo.2020.617400 · DOI
- Michelangeli, 1983, Mechanisms of calcitonin induction of prolonged activation of adenylate cyclase in human cancer cells, J Cyclic Nucleotide Protein Phosphor Res, 9, 129
- Motulsky, 1984, The kinetics of competitive radioligand binding predicted by the law of mass action, Mol Pharmacol, 25, 1, 10.1016/S0026-895X(25)15016-5 · DOI · Paper page
- Namkung, 2016, Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET, Nat Commun, 7, 12178, 10.1038/ncomms12178 · DOI · Paper page
- Olsen, 2020, TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome, Nat Chem Biol, 16, 841, 10.1038/s41589-020-0535-8 · DOI · Paper page
- Qi, 2013, Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function, Br J Pharmacol, 168, 644, 10.1111/j.1476-5381.2012.02197.x · DOI · Paper page
- Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy, Obesity (Silver Spring), 17, 1736, 10.1038/oby.2009.184 · DOI · Paper page
- Srivastava, 2018, Current pharmacotherapy for obesity, Nat Rev Endocrinol, 14, 12, 10.1038/nrendo.2017.122 · DOI · Paper page
- Tomabechi, 2013, Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists, Chemistry, 19, 15084, 10.1002/chem.201303303 · DOI · Paper page
- Udawela, 2006, A critical role for the short intracellular C terminus in receptor activity-modifying protein function, Mol Pharmacol, 70, 1750, 10.1124/mol.106.024257 · DOI
- Udawela, 2006, Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors, Mol Pharmacol, 69, 1984, 10.1124/mol.105.021915 · DOI
- Wells, 2016, Does salmon calcitonin cause cancer? A review and meta-analysis, Osteoporos Int, 27, 13, 10.1007/s00198-015-3339-z · DOI · Paper page
- Young, 1996, Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin, Drug Dev Res, 37, 231, 10.1002/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M · DOI · Paper page
- Zakariassen, 2020, Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice, Neuropharmacology, 167, 107987, 10.1016/j.neuropharm.2020.107987 · DOI · Paper page
Cited by
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Self-citationAmylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72
Lutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59
Metadata
- Authors
- Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 377
- Issue
- 3
- Pages
- 417-440
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W3138702158
- Cited by
- 68
- References
- 13
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1310 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. https://app.cochat.ai/papers/10.1124/jpet.121.000567
- The paper
- Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M. (2021). AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.121.000567
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.